Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
Kanji Takahashi,1 Masahito Ohji,2 Hiroko Terasaki,3 Shigeru Honda,4 Philippe Margaron,5 Tadhg Guerin,6 Mitsuko Yuzawa,7 On behalf of the EVEREST II Japanese investigators 1Department of Ophthalmology, Kansai Medical University, Osaka, Japan; 2Department of Ophthalmology, Shiga University...
Main Authors: | Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-09-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-ranibizumab-monotherapy-versus-ranibizumab-in-c-peer-reviewed-article-OPTH |
Similar Items
-
Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01) -
Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea
by: Young Gun Park, et al.
Published: (2015-04-01) -
Polypoidal Choroidal Vasculopathy: An Update on Therapeutic Approaches
by: Raymond L.M. Wong, et al.
Published: (2013-01-01) -
Comparison of Two-Year Outcome of Photodynamic Therapy in Combination with Intravitreal Aflibercept or Ranibizumab for Polypoidal Choroidal Vasculopathy
by: Hsin-Yu Weng, et al.
Published: (2021-01-01) -
Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
by: Kunbei Lai, et al.
Published: (2018-06-01)